Q-omics provides the consensus-scored PRRT2 profile across patient tissues and cancer cell-line models. PRRT2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PRRT2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PRRT2 RNA expression shows 18,964 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where PRRT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRRT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRRT2 survival associations across molecular data types. PRRT2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRRT2 RNA expression–survival associations across cancer types. High PRRT2 expression shows unfavorable associations in UVM, KIRC and COAD, but favorable associations in SKCM, HNSC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PRRT2 RNA expression.
This table summarizes PRRT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRRT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRRT2 shows lower tumor expression in KICH, UCEC and COAD and higher tumor expression in KIRC, LIHC and BRCA. The KIRC box plot shows higher PRRT2 RNA expression in tumor versus normal tissue (log2 FC = +0.604, t-test p < 0.001).
This table shows molecular features associated with PRRT2 in patient tissues and cancer cell lines. In patient samples, PRRT2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRRT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
